All.Can is committed to efficiency in cancer care. By working with all stakeholders, we aim to achieve our goal: better health outcomes for cancer patients. This is why we focus on finding, supporting and sharing evidence-based and measurable ways to improve cancer care.
The last structured Cancer Plan was introduced in 2008, at a time when there was still no coordinated policy framework for cancer care. In 2025, the question is whether a completely new Cancer Plan is truly necessary. What seems to be needed instead is a process of renewal and reflection.
All.Can Belgium is committed to efficiency in cancer care. But what exactly does that mean?
The All.Can Cancer Efficiency Metrics Study (2022) provides an answer to this question. Eight key metrics emerge from this comprehensive international study. These metrics can be used to assess and improve efficiency in cancer care.
All.Can Belgium is committed to efficiency in cancer care. But what exactly does that mean?
The All.Can Cancer Efficiency Metrics Study (2022) provides an answer to this question. Eight key metrics emerge from this comprehensive international study. These metrics can be used to assess and improve efficiency in cancer care.
All.Can Belgium uses these eight parameters to set up and evaluate projects. For example, our ‘Get Checked Early’ campaign emphasises the importance of timely diagnosis and therefore ties in with the first parameter (time to diagnosis).
The last structured Cancer Plan was introduced in 2008, at a time when there was still no coordinated policy framework for cancer care. In 2025, the question is whether a completely new Cancer Plan is truly necessary. What seems to be needed instead is a process of renewal and reflection.
2024 was a remarkable year for All.Can Belgium in many ways. Our actions attracted considerable attention, particularly from policymakers. In this annual report, we’ve brought everything together for you.
"If I hadn’t come down with flu-like symptoms in the autumn of 2016, I might not be here today." Robert Henkinet shares how a twist of fate led to the timely diagnosis of his bowel cancer – a stroke of luck. But his message is clear: "We can’t rely on…
On February 15, 2025, Johan Thibo passed away. As the founder and president of Prolong vzw, he dedicated many years to supporting people with lung cancer or pleural cancer and their loved ones. Thank you for your energy, Jo.
All.Can Belgium calls on policy makers to consider a national lung cancer screening program. Such a screening program can save lives, and there is both scientific evidence and public support for such a program.
Lina Vissenaeken, principal of a secondary school in East Flanders, has lived with a prosthetic knee for nearly 20 years after being diagnosed with osteosarcoma. “When I'm in pain, I limp, but my students are used to it now,” she says. Together with Cum Cura, a non-profit organization, she advocates…
Belgium is an internationally recognized leader in oncological research. Yet, the wave of innovations has not fully addressed cancer patients' needs. Advances in medication, digital technologies, and artificial intelligence necessitate a fresh perspective and a significant shift in mindset among policymakers and stakeholders in the healthcare sector.
Freya Rowaert (46) was diagnosed with synovial sarcoma, a rare form of cancer, when she was only 23. She has now lived with the disease for half of her life. A few years ago, she founded an online platform for fellow patients. "With 'Klare Kijk Op Kanker' (Clear View On…
According to feedback that UCL Saint-Luc collected from patients via its “Je Me GèRe” (JMGR) app, fatigue may be the biggest factor indirectly impacting the quality of life of people living with cancer. We talked to Frédéric Maddalena about the app’s impact and the new features that are available since…
Are you curious about what cancer care in Belgium will look like in the future? Then be sure to mark your calendar for November 6, 2024. On this day, All.Can Belgium will host the conference "Cancer Care: The Future is Now," focusing on the oncological (r)evolution in the 21st century…
